Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 03, 2025 07:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant...
October 03, 2025 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by...
August 13, 2025 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025$7.0 million royalty monetization agreement signed with Immedica Pharma AB for...
July 23, 2025 08:30 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Ovid Therapeutics to participate in the BTIG Virtual Biotech Conference
June 25, 2025 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain...
June 05, 2025 07:30 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will...
May 13, 2025 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Q1 earnings
April 02, 2025 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need,...
March 11, 2025 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move...
March 03, 2025 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant...